These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1339 related items for PubMed ID: 17205456

  • 21. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
    Palacios R, Senise J, Vaz M, Diaz R, Castelo A.
    HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
    [Abstract] [Full Text] [Related]

  • 22. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML, Rivas P, Molina M, Garcia R, De Górgolas M.
    Clin Infect Dis; 2005 Aug 01; 41(3):390-4. PubMed ID: 16007538
    [Abstract] [Full Text] [Related]

  • 23. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D, Berenguer J, Bellón JM, Miralles P, Cosin J, de Quiros JC, Conde MS, Muñoz-Fernández MA, Resino S.
    J Infect; 2008 Feb 01; 56(2):130-6. PubMed ID: 18192020
    [Abstract] [Full Text] [Related]

  • 24. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C, Lee S, Wong Kh, Cheng L, Lam M.
    HIV Med; 2007 Apr 01; 8(3):181-5. PubMed ID: 17461862
    [Abstract] [Full Text] [Related]

  • 25. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
    Kaplan JE, Hanson DL, Cohn DL, Karon J, Buskin S, Thompson M, Fleming P, Dworkin MS, Adult and Adolescent Spectrum of HIV Disease Project Investigators.
    Clin Infect Dis; 2003 Oct 01; 37(7):951-8. PubMed ID: 13130408
    [Abstract] [Full Text] [Related]

  • 26. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ, Till M, Palella FJ, Knoll MD, Terp SM, Kalnins AU, Murphy RL.
    HIV Med; 2005 Jan 01; 6(1):7-12. PubMed ID: 15670246
    [Abstract] [Full Text] [Related]

  • 27. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF, Price P, French MA.
    HIV Med; 2005 Jul 01; 6(4):278-83. PubMed ID: 16011533
    [Abstract] [Full Text] [Related]

  • 28. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
    Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS.
    HIV Med; 2006 Sep 01; 7(6):383-8. PubMed ID: 16903983
    [Abstract] [Full Text] [Related]

  • 29. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S, AIEDRP Network.
    J Infect Dis; 2006 Sep 15; 194(6):725-33. PubMed ID: 16941337
    [Abstract] [Full Text] [Related]

  • 30. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study.
    Arch Intern Med; 2003 May 26; 163(10):1220-6. PubMed ID: 12767960
    [Abstract] [Full Text] [Related]

  • 31. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 May 26; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 32. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 33. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.
    Antivir Ther; 2003 Oct 15; 8(5):379-84. PubMed ID: 14640384
    [Abstract] [Full Text] [Related]

  • 34. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
    Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.
    AIDS; 2006 Oct 24; 20(16):2021-32. PubMed ID: 17053348
    [Abstract] [Full Text] [Related]

  • 35. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Oct 24; 12(6):889-97. PubMed ID: 17926643
    [Abstract] [Full Text] [Related]

  • 36. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX.
    Chin Med J (Engl); 2006 Oct 20; 119(20):1677-82. PubMed ID: 17097013
    [Abstract] [Full Text] [Related]

  • 37. Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.
    Byakwaga H, Zhou J, Petoumenos K, Law MG, Boyd MA, Emery S, Cooper DA, Mallon PW.
    HIV Med; 2009 Mar 20; 10(3):143-51. PubMed ID: 19207595
    [Abstract] [Full Text] [Related]

  • 38. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM, Hogg RS, Braitstein P, Wood E, Yip B, Montaner JS.
    Antivir Ther; 2006 Mar 20; 11(1):125-9. PubMed ID: 16518968
    [Abstract] [Full Text] [Related]

  • 39. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May 20; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 40. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.